NCT03854110
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03854110
Title A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine (MIROC-1)
Acronym MIROC-1
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Persevere Therapeutics Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.